Acusphere, Inc.  

(Public, OTCMKTS:ACUS)   Watch this stock  
Find more results for NASDAQ:ACUS
0.0000 (0.00%)
Delayed:   12:46PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.01 - 0.30
Open 0.01
Vol / Avg. 28,080.00/617.00
Mkt cap 398,088.00
P/E     -
Div/yield     -
EPS -14.48
Shares 5.01M
Beta -0.56
Inst. own 0%

Key stats and ratios

Q4 (Dec '08) 2008
Net profit margin -3994.54% -2523.62%
Operating margin -2146.60% -1923.73%
EBITD margin - -1208.16%
Return on average assets -575.10% -180.30%
Return on average equity - -
Employees 118 -
CDP Score - -


99 Hayden Ave Ste 385
LEXINGTON, MA 02421-7998
United States - Map
+1-617-6488800 (Phone)
+1-978-8639993 (Fax)

Website links


Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).

Officers and directors

Martyn D. Greenacre Chairman of the Board
Age: 73
Mark W. Leuchtenberger President, Chief Executive Officer, Director
Age: 52
Sherri C. Oberg Vice Chairman of the Board
Trading Activity - Yahoo Finance
William I. Ramage Chief Development Officer
Age: 50
Garen G. Bohlin Director
Age: 67
Sandra L. Fenwick Director
Derek Lemke-von Ammon Director
Age: 52